⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Daichi Kasei Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Daichi Kasei Co., Ltd.
↗Fukusaki, Japan
Daichi Kasei Co., Ltd. is a specialized manufacturer of pharmaceutical active ingredients (APIs) and intermediates, headquartered in Fukusaki, Hyogo, Japan. Established in 1976, the company became a subsidiary of Towa Pharmaceutical Co., Ltd. in 2010, serving as a critical internal manufacturing and R&D arm for the group's generic drug production.
The company focuses on high-quality API synthesis, process development, and manufacturing. In recent years, it has expanded its capabilities to include high-potency API manufacturing and specialized analytical services, such as nitrosamine impurity testing, supporting both Towa Pharmaceutical's internal needs and broader industry requirements.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:1976
Ownership:subsidiary
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (API Manufacturer)
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Towa Pharmaceutical Co., Ltd.
Acquired By:Towa Pharmaceutical Co., Ltd. (2010-01-01)
Key Partnerships:Towa Pharmaceutical (Parent company and primary client)
COMPETITION
Position:Niche Player
Competitors:Other Japanese API manufacturers, Global CDMOs
LEADERSHIP
Key Executives:
Itsuro Yoshida - Chairman
LINKS
Website:daichikasei.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Daichi Kasei Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.